

PRODUCT INFORMATION

Common Name	HLX-20,HLX 43,HLX-43,HLX43,YL-222□Mab20
Conjugate	Unconjugated
Synonyms	Programmed cell death 1 ligand 1, B7H1, B7-H1, PDL1, PDCD1L1, B7 homolog 1, B7 homologue 1, CD274
Applications	ELISA, Flow Cyt
Endotoxin	Less than 1.0 EU/μg by the LAL method. For <1 EU/mg requirements, please contact us for customization.
Recommended Dilutions	ELISA 1:5000-10000, Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Homo sapiens Humanized
IgG type	Human IgG1(N297A)-lambda3
Reactivity	Human
Target	PD-L1
Uniprot ID	Q9NZQ7
Description	Anti-PD-L1(opucolimab biosimilar) mAb
Delivery	In Stock
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized antibodies are shipped at ambient temperature.
Sterility	Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 μm) prior to use.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only



Anti-PD-L1(opucolimab biosimilar) mAb ELISA

0.2 μ g of Human PD-L1, mFc-His tagged protein per well




Figure 1. ELISA plate pre-coated by 2 μ g/mL (100 μ L/well) Human PD-L1 Protein, mFc-His tag(PME100023) can bind Anti-PD-L1 (opucolimab biosimilar) mAb (BME100288) in a linear range of 8-40ng/mL.




Figure 2. Flow cytometry analysis with 0.5 μ g/ml Anti-PD-L1(opucolimab biosimilar) mAb (BME100288) on HEK293 cells transfected with human PD-L1 (Blue histogram) or HEK293 transfected with irrelevant protein (Red histogram).



PD-1 Competitive experiment of neutralizing anti-PD-L1 antibody




Figure 3. FACS analysis showed that the binding of Biotin-PD-1 to K562 cells overexpressing PD-L1 was inhibited by increasing concentrations of neutralizing anti-PD-L1 antibodies. The concentration of Biotin-PD-1 used was 1.5 $\mu\text{g}/\text{mL}$. BME100288 and BME100287 exhibited dose-dependent blocking activity, while the irrelevant control antibody showed no inhibition.

